☰

David J. VanderWeele, Ph.D. - Publications

Affiliations: 
2005 University of Chicago, Chicago, IL 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 VanderWeele DJ, Kocherginsky M, Munir S, Martone B, Sagar V, Morgans A, Stadler WM, Abdulkadir S, Hussain M. A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 36210299 DOI: 10.1016/j.clgc.2022.08.012  0.311
2020 VanderWeele DJ, Hussain M. PARP inhibitors in prostate cancer: practical guidance for busy clinicians. Clinical Advances in Hematology & Oncology : H&O. 18: 808-815. PMID 33406057  0.316
2020 Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, Jansson KH, Beshiri ML, Agarwal S, Rodriguez-Nieves JA, Capaldo B, Kelly K, VanderWeele DJ. Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. Molecular Cancer Therapeutics. PMID 32371590 DOI: 10.1158/1535-7163.Mct-19-0936  0.424
2020 Wilkinson S, Harmon SA, Terrigino NT, Karzai F, Pinto PA, Madan RA, VanderWeele DJ, Lake R, Atway R, Bright JR, Carrabba NV, Trostel SY, Lis RT, Chun G, Gulley JL, et al. A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications. 11: 837. PMID 32054861 DOI: 10.1038/S41467-020-14657-7  0.359
2020 Meeks JJ, Shilatifard A, Miller SD, Morgans AK, VanderWeele DJ, Kocherginsky M, Hussain MHA. A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183). Journal of Clinical Oncology. 38: TPS607-TPS607. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps607  0.336
2020 Numan Y, Zhao J, Tang S, Zhang Y, Zhang Q, Jovanovic B, VanderWeele DJ, Morgans AK, Cristofanilli M, Yu J, Hussain MHA. Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response. Journal of Clinical Oncology. 38: TPS275-TPS275. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps275  0.431
2020 Burns MC, Sagar V, Jovanovic B, Morgans AK, VanderWeele DJ, Quinn DI, Stadler WM, Abdulkadir S, Hussain MHA. A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: TPS274-TPS274. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps274  0.444
2020 Wilkinson SC, Ye H, Terrigino N, Carrabba N, Atway R, Trostel SY, Bright J, Hennigan ST, Lis R, Lake R, Harmon S, Turkbey B, Pinto PA, Choyke PL, Karzai F, ... VanderWeele DJ, et al. Multiple primary prostate tumors with differential drug sensitivity. Journal of Clinical Oncology. 38: 342-342. DOI: 10.1200/Jco.2020.38.6_Suppl.342  0.385
2019 Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, Current, and Future of Immunotherapies for Prostate Cancer. Frontiers in Oncology. 9: 884. PMID 31572678 DOI: 10.3389/Fonc.2019.00884  0.403
2019 VanderWeele DJ, Antonarakis ES, Carducci MA, Dreicer R, Fizazi K, Gillessen S, Higano CS, Morgans AK, Petrylak DP, Sweeney CJ, Hussain M. Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901595. PMID 31498754 DOI: 10.1200/Jco.19.01595  0.337
2019 VanderWeele DJ, Meeks JJ, Hussain M. Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer? Translational Andrology and Urology. 8: S91-S92. PMID 31143677 DOI: 10.21037/Tau.2018.12.07  0.319
2019 Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, Madan RA, Choyke PL, Turkbey B, et al. mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. Urologic Oncology. PMID 31000430 DOI: 10.1016/J.Urolonc.2019.01.012  0.329
2019 Zarzour A, Morgans AK, Palmbos PL, Jovanovic B, Tomlins SA, VanderWeele DJ, Yang XJ, Schaeffer EM, Sharifi R, Meeks JJ, Abdulkadir S, Hussain MHA. Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa). Journal of Clinical Oncology. 37: TPS333-TPS333. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps333  0.359
2019 Karzai F, Madan RA, VanderWeele DJ, Chun G, Bilusic M, Cordes LM, Carrabba N, Wilkinson S, Ye H, Harmon S, Sowalsky AG, Turkbey B, Pinto PA, Choyke PL, Gulley JL, et al. A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI). Journal of Clinical Oncology. 37: 63-63. DOI: 10.1200/Jco.2019.37.7_Suppl.63  0.372
2019 Sowalsky AG, Wilkinson S, Ye H, Harmon S, Turkbey B, Carrabba N, Atway R, Chun G, VanderWeele DJ, Karzai F, Madan RA, Pinto PA, Choyke PL, Dahut WL. Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide. Journal of Clinical Oncology. 37: 61-61. DOI: 10.1200/Jco.2019.37.7_Suppl.61  0.376
2019 Chen G, VanderWeele DJ, Karzai F, Bilusic M, Al Harthy M, Arlen PM, Rosner IL, Chun G, Owens H, Couvillon A, Hankin A, Williams M, Cordes LM, Figg WD, Gulley JL, et al. Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer. Journal of Clinical Oncology. 37: 241-241. DOI: 10.1200/Jco.2019.37.7_Suppl.241  0.366
2019 Chen G, VanderWeele DJ, Karzai F, Bilusic M, Al Harthy M, Arlen PM, Theoret MR, Rosner IL, Chun G, Owens H, Couvillon A, Hankin A, Williams M, Gulley JL, Dahut WL, et al. Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis. Journal of Clinical Oncology. 37: e16536-e16536. DOI: 10.1200/Jco.2019.37.15_Suppl.E16536  0.366
2019 Adelaiye-Ogala RM, Kelly K, VanderWeele D. Abstract LB-262: Targeting of the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting the induction of glucocorticoid receptor Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-262  0.309
2019 Wilkinson S, Ye H, Carrabba N, Atway R, Trostel SY, Hennigan T, Lake R, Harmon S, Chun G, Turkbey B, Pinto PA, Choyke PL, Karzai F, VanderWeele DJ, Kelly K, et al. Abstract 2510: Combining genetic and histopathologic features to predict response to anti-androgen therapy in aggressive prostate cancer Cancer Research. 79: 2510-2510. DOI: 10.1158/1538-7445.Am2019-2510  0.435
2018 Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. Journal For Immunotherapy of Cancer. 6: 141. PMID 30514390 DOI: 10.1186/S40425-018-0463-2  0.409
2018 VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, Pontier A, Nguyen YTM, Maejima K, Sasaki-Oku A, Nakano K, et al. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. European Urology Focus. PMID 29398457 DOI: 10.1016/J.Euf.2018.01.006  0.355
2018 VanderWeele DJ, Turkbey B, Karzai F, Harmon S, Sowalsky AG, Ye H, Wilkinson S, Chun G, Gold S, Pinto PA, Choyke PL, Dahut WL. Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial. Journal of Clinical Oncology. 36: 94-94. DOI: 10.1200/Jco.2018.36.6_Suppl.94  0.383
2018 Sowalsky AG, Wilkinson S, Ye H, VanderWeele DJ, Turkbey B, Hennigan ST, Atway R, Trostel SY, Lake R, Karzai F, Harmon S, Chun G, Kelly K, Pinto PA, Choyke PL, et al. Molecular and histopathologic correlates of imaging and biological responses to neoadjuvant GnRH agonist plus enzalutamide for high risk prostate cancer. Journal of Clinical Oncology. 36: 34-34. DOI: 10.1200/Jco.2018.36.6_Suppl.34  0.406
2018 VanderWeele DJ, Turkbey B, Karzai F, Harmon S, Sowalsky AG, Ye H, Wilkinson S, Chun G, Gold SA, Pinto PA, Choyke PL, Dahut WL. Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses. Journal of Clinical Oncology. 36: 5082-5082. DOI: 10.1200/Jco.2018.36.15_Suppl.5082  0.302
2018 Adelaiye-Ogala RM, Nguyen YT, Rodriguez-Nieves JA, Alilin AN, Agarwal S, Vanderweele D. Abstract 5787: Ipatasertib impairs tumor growth in androgen sensitive and castrate resistant prostate cancer: Evidence in preclinical models Cancer Research. 78: 5787-5787. DOI: 10.1158/1538-7445.Am2018-5787  0.433
2018 Nguyen YT, Rodriguez-Nieves JA, Yang Q, VanderWeele D. Abstract 5420: Nuclear PTEN directly regulates androgen receptor activity in prostate cancer Cancer Research. 78: 5420-5420. DOI: 10.1158/1538-7445.Am2018-5420  0.412
2018 Gold S, Marhamati S, Harmon S, Bloom J, Karzai F, Hale G, Rayn K, Sabarwal V, Mehralivand S, Czarniecki M, Smith C, VanderWeele D, Dahut W, Turkbey B, Pinto P. PD14-05 NEOADJUVANT ENZALUTAMIDE AND ANDROGEN DEPRIVATION IN HIGH-RISK PROSTATE CANCER: INITIAL IMAGING AND SURGICAL FINDINGS FROM A PHASE II CLINICAL TRIAL Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.791  0.31
2017 Gillard M, Lack J, Pontier A, Gandla D, Hatcher D, Sowalsky AG, Rodriguez-Nieves J, Vander Griend D, Paner G, VanderWeele D. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. European Urology Focus. PMID 29229583 DOI: 10.1016/J.Euf.2017.12.003  0.365
2017 Lack J, Gillard M, Cam M, Paner GP, VanderWeele DJ. Circulating tumor cells capture disease evolution in advanced prostate cancer. Journal of Translational Medicine. 15: 44. PMID 28228136 DOI: 10.1186/S12967-017-1138-3  0.403
2017 VanderWeele DJ, Lack J, Gillard M, Cam M, Paner G. Genomic analysis of untreated prostate adenocarcinoma, treatment-emergent neuroendocrine carcinoma, and circulating tumor cells. Journal of Clinical Oncology. 35: 200-200. DOI: 10.1200/Jco.2017.35.6_Suppl.200  0.368
2016 McCann SM, Jiang Y, Fan X, Wang J, Antic T, Prior F, VanderWeele D, Oto A. Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study. Ajr. American Journal of Roentgenology. 206: 559-65. PMID 26901012 DOI: 10.2214/Ajr.15.14967  0.348
2015 VanderWeele DJ, Paner GP, Fleming GF, Szmulewitz RZ. Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report. Frontiers in Oncology. 5: 169. PMID 26258074 DOI: 10.3389/Fonc.2015.00169  0.395
2015 Packiam VT, Patel SG, Pariser JJ, Richards KA, Weiner AB, Paner GP, VanderWeele DJ, Zagaja GP, Eggener SE. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 86: 777-82. PMID 26196240 DOI: 10.1016/J.Urology.2015.07.009  0.325
2015 VanderWeele DJ, McCann S, Fan X, Antic T, Jiang Y, Oto A. Radiogenomics of prostate cancer: Association between qunatitative multiparametric MRI features and PTEN. Journal of Clinical Oncology. 33: 126-126. DOI: 10.1200/Jco.2015.33.7_Suppl.126  0.361
2014 Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. Journal of Translational Medicine. 12: 313. PMID 25424879 DOI: 10.1186/S12967-014-0313-Z  0.423
2014 VanderWeele DJ, Brown CD, Taxy JB, Gillard M, Hatcher DM, Tom WR, Stadler WM, White KP. Low-grade prostate cancer diverges early from high grade and metastatic disease. Cancer Science. 105: 1079-85. PMID 24890684 DOI: 10.1111/Cas.12460  0.372
2014 VanderWeele DJ, Isikbay M, Reyes E, Duggan R, Wyche AJ, Stadler WM, Vander Griend D, Szmulewitz RZ. Feasibility of multimodal molecular characterization of the androgen receptor (AR) in circulating tumor cells (CTCs) from patients with castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 32: 133-133. DOI: 10.1200/Jco.2014.32.4_Suppl.133  0.422
2013 VanderWeele DJ, Brown CD, Grossman RL, Taxy JB, Stadler WM, White KP. The genomic relationship among matched prostate cancer foci. Journal of Clinical Oncology. 31: 5028-5028. DOI: 10.1200/Jco.2013.31.15_Suppl.5028  0.364
2009 Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R, Den Boer ML. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 113: 2014-21. PMID 18978206 DOI: 10.1182/Blood-2008-05-157842  0.514
2005 Vanderweele DJ, Rudin CM. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. Molecular Cancer Research : McR. 3: 635-44. PMID 16317089 DOI: 10.1158/1541-7786.Mcr-05-0063  0.505
2005 Brace JL, Vanderweele DJ, Rudin CM. Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in Saccharomyces cerevisiae. Yeast (Chichester, England). 22: 641-52. PMID 16034825 DOI: 10.1002/Yea.1235  0.638
2004 VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Molecular Cancer Therapeutics. 3: 1605-13. PMID 15634654  0.472
2003 Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Research. 63: 312-8. PMID 12543781  0.501
2002 Vander Heiden MG, Choy JS, VanderWeele DJ, Brace JL, Harris MH, Bauer DE, Prange B, Kron SJ, Thompson CB, Rudin CM. Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism. The Journal of Biological Chemistry. 277: 44870-6. PMID 12244097 DOI: 10.1074/Jbc.M204888200  0.614
Show low-probability matches.